ValuEngine Lowers Natera (NTRA) to Hold

Natera (NASDAQ:NTRA) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday.

NTRA has been the subject of a number of other reports. Craig Hallum began coverage on shares of Natera in a research report on Monday, April 9th. They set a “buy” rating and a $16.00 price target for the company. Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. BidaskClub upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, Morgan Stanley lifted their price target on shares of Natera from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.80.

Get Natera alerts:

Natera traded down $0.25, reaching $11.47, during trading on Monday, MarketBeat Ratings reports. 244,198 shares of the stock were exchanged, compared to its average volume of 137,967. The company has a debt-to-equity ratio of -18.90, a current ratio of 1.80 and a quick ratio of 1.68. Natera has a 1 year low of $11.42 and a 1 year high of $11.95. The company has a market capitalization of $638.89 million, a PE ratio of -4.78 and a beta of 2.07.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. The firm had revenue of $62.34 million for the quarter, compared to analysts’ expectations of $54.86 million. During the same period last year, the firm earned ($0.70) earnings per share. Natera’s revenue for the quarter was up 26.2% on a year-over-year basis. sell-side analysts forecast that Natera will post -2.05 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Trexquant Investment LP acquired a new stake in shares of Natera during the first quarter valued at about $119,000. MetLife Investment Advisors LLC acquired a new stake in shares of Natera during the fourth quarter valued at about $124,000. Jefferies Group LLC acquired a new position in shares of Natera in the fourth quarter valued at approximately $130,000. Wells Fargo & Company MN grew its holdings in shares of Natera by 69.2% in the third quarter. Wells Fargo & Company MN now owns 30,504 shares of the medical research company’s stock valued at $393,000 after purchasing an additional 12,473 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Natera by 13.2% in the first quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock valued at $444,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors and hedge funds own 68.51% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Natera (NASDAQ:NTRA)